GiveBetter x New York City

St. Ann's Corner of Harm Reduction

Whole recipient; conditional integrated harm reduction, clinical care and net household resources

Research time: ~4 min on GPT-6 Astra Light + ~15 min on GPT-6.1 Sol
  • Research — reviewed programs, finances and impact evidence.
  • Modeling — estimated costs, QALYs and uncertainty.
  • Source audit — checked claims, assumptions and calculations.

Updated: 2026-10-05

Donate

Summary

What do they do? St. Ann's Corner of Harm Reduction provides a South Bronx health hub with overdose prevention, sterile supplies, buprenorphine access and ongoing care coordination. Meals, hygiene, outreach and a current workforce initiative support many of the same participants, so their health and economic effects need a shared cohort and clear accounting. We examine additional integrated engagement supported by an ordinary gift, with the whole recipient's costs and net household resources rather than the retail value of free supplies.

Why we’re interested in this organization:

  • Current clinical, outreach and LUCHA workforce pages identify concrete services and current enrollment, rather than only a historical mission statement.

  • Three original annual returns reconcile the full recipient's operating and event costs and reveal its reliance on government grants.

  • One unique-person survival comparison and signed household-resource ledger avoid assigning every rescue another lifetime or treating every free item as a cash saving.

Our main reservations:

  • No current unique clinical cohort, retained-treatment series, net employment outcomes or gift-funded engagement queue was found; outcome and capacity priors remain judgments.

  • NYC supplies free naloxone and other providers continue care, so extra distribution or a referral does not prove an incremental health benefit.

  • The conditional estimate is about $2.2M per DALY; net household-resource effects are slightly negative centrally, and low-benefit or adverse scenarios have no positive finite price.

What do you get for your dollar? $2.2M per DALY in New York City. DALY is our one-year comparison unit. QALY-based health gains and income-welfare equivalents retain their original assumptions; they are not measured clinical DALYs. Conditional whole-recipient donor-funded additional engagement; current combined health and signed household-resource estimate. Initial health-only model retained separately as a diagnostic..

For$10K normalization,E=1.0692042041443433 modeled additional engagements; household equivalents=0.8553633633154747; clinical-access-equivalent factor a=.5; higher-risk fraction .6. Mortality=0.00296730533643539, morbidity=0.001843635323500151, harm=0.00010539359609088062 all-population health years. MSA health=0.004611436122567768, signed economic equivalents=-0.0001327513760614531; combined=0.004478684746506314. Native units are mathematical engaged-person equivalents, not observed retained patients or additional rescue counts.

1. What do they do?

The ordinary charitable recipient is St. Ann's Corner of Harm Reduction Inc., EIN 13-3724008, as its donation page confirms. Its South Bronx hub offers overdose prevention, sterile supplies, HIV/HCV testing and treatment linkage, buprenorphine and wound care. The current programs also describe meals, hygiene and behavioral care; these are overlapping services for the same people, not separate additive patient populations. The site includes nonstandard holistic modalities; this model does not assign acupuncture, Reiki or every social activity a clinical effect.

The LUCHA workforce page, retrieved directly when the browser wrapper failed, advertises eight weekly sessions, job readiness, financial/computer literacy, interview and resume support, coaching and summer/fall 2026 and winter 2027 enrollment options. It identifies Hispanic Federation and Fund for the City of New York support. That establishes advertised services and a possible employment mechanism, not measured placements or wage gains. This is a whole-recipient gift comparison, not a newly invented restricted clinical/workforce fund.

2. Monitoring and information sharing

The annual-impact page still ties 2,816 unique participants, 851,689 services and 24,851 meals to its 2023 report. These are historical reach/output totals. Repeat services, meals, tests and medical contacts are not completed treatments or unique lives saved. The image-only annual-report interpretation from the alpha review is preserved as earlier evidence; it was not freshly visually audited in this revision. Current drop-in and workforce pages confirm ongoing offers but do not supply a fresh annual unique cohort.

Useful monitoring would link a privacy-preserving unique cohort to engagement intensity, buprenorphine initiation and retention, alternative-provider access, repeat overdose outcomes, wound/infection outcomes, quality of life, household costs and actual disposable pay. Address-based MSA residency, repeat households, food purchase versus unmet consumption and failed applicants need measurement. A dated additional-staff/slots workplan and covered versus uncovered grant commitments would identify marginal capacity. This review makes no contact or enrollment and treats current scale transfer as a judgment.

3. Qualitative assessment

The clinical case is strongest for maintaining access to effective opioid treatment and timely overdose response. The Sordo primary synthesis associates treatment with lower mortality, but in/out-treatment contrasts are observational and include treatment selection, cycling and older drug markets. Its buprenorphine rates cannot simply become a local hub effect. A British Columbia fentanyl-era cohort supports retention relevance while remaining an observational comparison in a different health system.

Contemporary implementation evidence constrains optimism. The original HEALing Communities mortality trial, retained from alpha, found no statistically significant mortality reduction; the newly read 2025 secondary randomized analysis found no improvement in MOUD receipt, 180-day retention or linkage after relevant acute-care encounters. Community-wide implementation differs from SACHR's selected participants, but a promising bundle does not guarantee causal uptake. We therefore use modest explicitly judged mortality/utility differences and retain zero and adverse alternatives.

The central utility change represents residual clinical/function benefit among people alive in both worlds. It is not an independently measured generic utility effect or a claim that every social service improves health. Food, consumption and workforce channels are separately signed; half of positive economic welfare is retained to limit overlap with generic wellbeing, while negative cash burdens remain fully charged. Survival benefits do not receive extra ordinary lifetime earnings. Dignity, HIV/HCV transmission, housing navigation and broader employment/community effects remain unpriced, rather than assumed literally absent. This is a partial conditional research model, not a complete expected-value estimate or donor-ready recommendation.

4. What do you get for your dollar?

Our conditional estimate is about $2.2M per DALY: one modeled equivalent year for NYC metro residents. The initial health-only estimate was $1.4M. The revision changes clinical assumptions, survival accounting, delay and harms as well as adding net household resources; it does not mean measured performance deteriorated.

What additional money could provide. The latest full-recipient annual cost is $5.27 million. Applying a judgment about current scale to historical unique reach implies roughly $2,338 in average organizational support per annual engagement equivalent. With an assumed 25% funding response, that becomes about $9,353 in donor funding per additional engagement. These are conditional calculations, not verified marginal prices, additional treatment completions or available slots. Shared administration, fundraising and event expenses enter the denominator once.

Health benefits. The central case assumes a modest one-year reduction in mortality among a high-risk subgroup, plus a small improvement in clinical functioning among people alive in both worlds. Treatment starts after three months; the survival comparison is capped at ten years, with no permanent mortality reduction or separate lifetime credit for each overdose rescue. High- and lower-risk groups have different baseline hazards, replacing the initial uniform 8% annual hazard. A small independent health burden remains even when clinical benefits disappear. These are explicit judgments, not locally measured treatment effects.

Net household resources. The model distinguishes households whose meals and hygiene supplies replace purchases from households receiving otherwise unmet consumption. It subtracts additional travel costs, actually lost disposable pay and medicine or copay costs after assistance and alternative care. A small workforce-response scenario adds net disposable earnings after taxes, benefits, work expenses and other-provider substitution. SACHR's workforce page establishes an offered program, not a measured placement or wage effect. Free naloxone receives no automatic retail purchase-saving credit.

Following Coefficient Giving's logarithmic comparison, the economic calculation uses a judged $20,000 annual household-resource baseline and converts dated net resource changes into healthy-year equivalents. Baseline survival, NYC attribution and discounting apply once. Half of positive economic welfare is retained to limit overlap with generic wellbeing; negative resource burdens remain fully charged. Newly surviving participants receive no additional credit for ordinary baseline earnings. Actual purchases, unmet consumption and nested medical payments use a shared cash ledger to avoid duplicate benefits or inconsistent logarithms.

At a $10,000 mathematical normalization—not a gift recommendation—the central model produces about 0.00 health years and 0.00 income-equivalent years, or 0.00 combined years. Scaling costs and engagement together leaves the price unchanged. Every assumption and signed pathway is recorded in the appendix.

Uncertainty and scope. A favorable bundled scenario is approximately $157K per DALY; a weak-response, higher-burden scenario is net negative. Zero expansion gives zero effects. Clinical-null and complete clinical-substitution cases retain costs and harms. A selected external-resource companion adds $2,000 per additional engagement for unrecognized clinical, public-stock and volunteer inputs, giving approximately $2.7M at the same welfare result; this is not a complete net societal-cost estimate. No duplicate procurement expense or public-stock saving is added. Unmeasured other-program effects and actual funding response could dominate this partial model.

Model, assumptions and sensitivity

Donor-cost marginal-engagement scenario using latest gross whole-recipient annual expense/current-transferred historical reach as average cost prior. Annual accounting scope is distinct from gift response; full budget charged once, no program-share recosting. Selected external resources separate.

g=.98 subjectively identifies resident MSA outcomes from Bronx/nearby-borough service; official NYC edition uses22county OMB MSA. Income paths have editionShare once; editionQalys is health only.

k=ln(1+r); F(v,t)=(1-exp(-v*t))/v; E=G*b*N*f/C; B=u*(F(mH-delta+k,1)-F(mH+k,1)+(exp(-(mH-delta))-exp(-mH))*exp(-k)*F(mH+k,T-1)); H=E*a*(z*exp(-(mH+k)*L)*B+p*v*(z*exp(-(mH+k)*L)*F(mH+k,1)+(1-z)*exp(-(mL+k)*L)*F(mL+k,1)))-E*h*S0(L)*exp(-k*L); S0(t)=z*exp(-mH*t)+(1-z)*exp(-mL*t). Economic paths: .5*people*ln(1+gain/base)*S0(receipt)*g*independentShare/(1+r)^receipt for each one-off/year receipt. Joint-stratum bases follow burden then receipt then medicine; negative effects independence1. Price10=10*(G+E*external)/(g*H+sum economic paths), null if combined<=0.

G
10000 USD gift normalization (judgment). Mathematical scale only; price invariant under linear scaling. [programs] [return2025]
C
5267469 USD gross annual recipient expense (observed). Fresh original FY2025 PartIX plus separately netted event expense. [return2025] [schedule2025]
N
2816 historical unique participants (observed). Historical2023 page count, not current clinical completions. [impact]
f
0.8 current-scale fraction (judgment). 80%transfer of older reach; no current cohort found. [programs] [return2025]
b
0.25 incremental funded scale response (judgment). 25%ordinary-gift operating/capacity prior; grants, reserves and renewals can replace support. [programs] [return2025]
a
0.5 clinical access additionality (judgment). 50%net clinical access advantage after other providers/public supplies, distinct from funding response. [clinical-primary] [fentanyl-cohort] [heal-moud25] [nyc-naloxone]
z
0.6 high-risk share (judgment). 60%unverified higher opioid-risk fraction; rest assigned lower mortality. [programs] [return2025]
mHigh
0.04 annual continuous hazard (judgment). 4%planning prior, not local observed risk; primary cohorts have heterogeneous treatment/risk populations. [clinical-primary] [fentanyl-cohort] [heal-moud25] [nyc-naloxone]
mLow
0.01 annual continuous hazard (judgment). 1%lower-risk planning prior, replacing uniform8% hazard. [clinical-primary] [fentanyl-cohort] [heal-moud25] [nyc-naloxone]
delta
0.002 first-year hazard difference (judgment). 0.002modest integrated-package prior, not imported treatment contrast or summed rescue attribution. [clinical-primary] [fentanyl-cohort] [heal-moud25] [nyc-naloxone]
u
0.7 baseline utility (judgment). 0.7unmeasured baseline for extra survival, without adding ordinary earnings. [programs] [return2025]
T
10 post-engagement years (judgment). Ten-year finite survival valuation cap; no permanent hazard advantage after first year. [programs] [return2025]
p
0.12 clinical responder share (judgment). 12%additional one-year utility response, not measured program yield. [clinical-primary] [fentanyl-cohort] [heal-moud25] [nyc-naloxone]
v
0.03 annual utility gain (judgment). 0.03generic clinical utility prior; null and stronger response tested. [clinical-primary] [fentanyl-cohort] [heal-moud25] [nyc-naloxone]
L
0.25 years to engagement (judgment). Quarter-year delay, with pre-engagement mortality and discounting. [programs] [return2025]
r
0.03 annual discount rate (judgment). 3%financial/welfare time preference. [programs] [return2025]
g
0.98 MSA outcome share (judgment). 98%residence prior, not address data; geography applied once. [programs] [return2025]
h
0.0001 health-years burden per new engagement (judgment). Independent small net iatrogenic/delay burden; not a measured safety upper bound. [programs] [return2025]
households
0.8 household equivalents per participant (judgment). 0.8deduplication prior; no family-size multiplier. [impact] [dropin-current] [income-cg]
Y
20000 USD annual household resources (judgment). 20Kwhole-household consumption/disposable-resource reference, unmeasured;10Kstress. [programs] [income-cg]
buyer
0.25 would-buy household share (judgment). 25%disjoint incremental purchase-saving incidence after other food/help routes. [impact] [dropin-current] [income-cg]
saving
40 USD actual purchase saving (judgment). 40once-only actual food/hygiene expenditure difference, not retail/free naloxone. [impact] [dropin-current] [income-cg]
unmet
0.25 unmet-consumption household share (judgment). 25%disjoint would-not-buy usable in-kind group; cannot overlap buyers. [impact] [dropin-current] [income-cg]
consumption
20 USD useful consumption equivalent (judgment). 20once-only usable food/hygiene value, not procurement/retail cost assumed automatically. [impact] [dropin-current] [income-cg]
travel
10 USD net added travel (judgment). 10actual cash beyond assistance and counterfactual visits. [programs] [income-cg]
missed
5 USD net lost pay (judgment). 5actual lost disposable pay after leave/benefits; not leisure time. [workforce-current] [income-cg]
medicineShare
0.1 household medicine-payment share (judgment). 10%nested net copay/medicine incidence, not every medical service. [programs] [income-cg]
medicine
20 USD net added medicine cost (judgment). 20after insurance and alternative care; nested resource base preserves logs. [programs] [income-cg]
workShare
0.02 incremental workforce/recovery responder share (judgment). 2%across new engagements; includes participation, eligibility and other-provider substitution. [workforce-current] [income-cg]
earnings
300 USD net extra annual disposable pay (judgment). 300after tax/benefit/work expenses; no published SACHR wage effect. [workforce-current] [income-cg]
earnYears
1 years of earnings receipt (judgment). One year centrally, two only in favorable case; not mortality tail. [workforce-current] [income-cg]
workDelay
1.25 years to first earnings (judgment). 1.25years after normalization, after the initial course year. [workforce-current] [income-cg]
positiveIndependent
0.5 positive economic welfare independent share (judgment). 50%positive credit to reduce clinical/generic-wellbeing overlap; negative costs always100%. [programs] [income-cg]
external
0 USD external resources per new engagement (judgment). Zero extra denominator addback centrally because inventory unknown, not evidence resources cost nothing;2Kselected-resource companion. [programs] [return2025]

Conditional integrated care and net resources: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.00296730533643539; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=-0.0001327513760614531; unweighted judgment case, not confidence interval.

Small clinical response, weak funding and net resource costs: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.5,"b":0.1,"a":0.2,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.0005,"u":0.7,"T":3,"p":0.05,"v":0.01,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.1,"saving":20,"unmet":0.1,"consumption":10,"travel":25,"missed":15,"medicineShare":0.2,"medicine":40,"workShare":0.005,"earnings":100,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=0.2673010510360858; mortality=0.00002448882517032631; morbidity=0.000025606046159724326; harm=0.000026348399022720155; MSA income-equivalent=-0.0002324271556019479; unweighted judgment case, not confidence interval.

Stronger additional engagement and useful household gains: Cost: $10K; New York City health QALYs: 0.06; all-population health QALYs: 0.06. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":1,"b":0.5,"a":0.75,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.006,"u":0.7,"T":15,"p":0.2,"v":0.05,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.3,"saving":80,"unmet":0.3,"consumption":40,"travel":5,"missed":0,"medicineShare":0.1,"medicine":20,"workShare":0.05,"earnings":600,"earnYears":2,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=2.673010510360858; mortality=0.04393703172848091; morbidity=0.019204534619793247; harm=0.0002634839902272015; MSA income-equivalent=0.0019520835150741885; unweighted judgment case, not confidence interval.

No gift-induced expansion: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=0; mortality=0; morbidity=0; harm=0; MSA income-equivalent=0; unweighted judgment case, not confidence interval.

No clinical change; extra burdens and no useful receipts: Cost: $10K; New York City health QALYs: -0.01; all-population health QALYs: -0.01. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0,"u":0.7,"T":10,"p":0,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.005,"households":0.8,"Y":20000,"buyer":0,"saving":40,"unmet":0,"consumption":20,"travel":40,"missed":20,"medicineShare":0.1,"medicine":20,"workShare":0,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0; morbidity=0; harm=0.0052696798045440306; MSA income-equivalent=-0.0012464277317268345; unweighted judgment case, not confidence interval.

No mortality or morbidity benefit; signed resources remain: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0,"u":0.7,"T":10,"p":0,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0; morbidity=0; harm=0.00010539359609088062; MSA income-equivalent=-0.0001327513760614531; unweighted judgment case, not confidence interval.

Alternative care removes clinical advantage; engagement costs remain: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0; morbidity=0; harm=0.00010539359609088062; MSA income-equivalent=-0.0001327513760614531; unweighted judgment case, not confidence interval.

No useful food, consumption or workforce gain; costs remain: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0,"saving":40,"unmet":0,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.00296730533643539; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=-0.0003413906668734993; unweighted judgment case, not confidence interval.

All positive economic welfare overlaps clinical wellbeing: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0,"external":0}; E=1.0692042041443433; mortality=0.00296730533643539; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=-0.00034136053342729883; unweighted judgment case, not confidence interval.

All positive household welfare independent of health: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":1,"external":0}; E=1.0692042041443433; mortality=0.00296730533643539; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=0.00007585778130439262; unweighted judgment case, not confidence interval.

Only 10% funded scale response: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.1,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=0.42768168165773734; mortality=0.001186922134574156; morbidity=0.0007374541294000605; harm=0.00004215743843635224; MSA income-equivalent=-0.00005310055042458124; unweighted judgment case, not confidence interval.

8% high-risk baseline hazard: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.08,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.002446390321843797; morbidity=0.0018115534191822024; harm=0.00010476627484792363; MSA income-equivalent=-0.00013107191948734636; unweighted judgment case, not confidence interval.

2% high-risk baseline hazard: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.01. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.02,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.003282489071156615; morbidity=0.001860092781682371; harm=0.00010570961702325492; MSA income-equivalent=-0.00013359729476811275; unweighted judgment case, not confidence interval.

One-year engagement delay: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":1,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":2,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.002816472302142524; morbidity=0.001766062283395956; harm=0.00010095089732099973; MSA income-equivalent=-0.0001271612639862243; unweighted judgment case, not confidence interval.

Three-year survival valuation cap: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":3,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.000980234760822331; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=-0.0001327513760614531; unweighted judgment case, not confidence interval.

No donor-caused survival effect: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=-0.0001327513760614531; unweighted judgment case, not confidence interval.

No additional clinical utility change: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.00296730533643539; morbidity=0; harm=0.00010539359609088062; MSA income-equivalent=-0.0001327513760614531; unweighted judgment case, not confidence interval.

Selected unrecognized medication/volunteer/public resources: Cost: $12K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":2000}; E=1.0692042041443433; mortality=0.00296730533643539; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=-0.0001327513760614531; unweighted judgment case, not confidence interval.

10K annual household consumption-resource reference: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":10000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.00296730533643539; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=-0.0002666461647735755; unweighted judgment case, not confidence interval.

Net employment/disposable-pay effect negative: Cost: $10K; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. {"G":10000,"C":5267469,"N":2816,"f":0.8,"b":0.25,"a":0.5,"z":0.6,"mHigh":0.04,"mLow":0.01,"delta":0.002,"u":0.7,"T":10,"p":0.12,"v":0.03,"L":0.25,"r":0.03,"g":0.98,"h":0.0001,"households":0.8,"Y":20000,"buyer":0.25,"saving":40,"unmet":0.25,"consumption":20,"travel":10,"missed":5,"medicineShare":0.1,"medicine":20,"workShare":0.02,"earnings":-300,"earnYears":1,"workDelay":1.25,"positiveIndependent":0.5,"external":0}; E=1.0692042041443433; mortality=0.00296730533643539; morbidity=0.001843635323500151; harm=0.00010539359609088062; MSA income-equivalent=-0.0003087474032954391; unweighted judgment case, not confidence interval.

Historical alpha diagnostic: Integrated health-hub conditional scenario: Cost: $5.3M; New York City health QALYs: 3.91; all-population health QALYs: 3.99. Preserved20260914 health-only alpha; not current combined result. {"C":5267469,"N":2816,"f":0.8,"z":0.6,"delta":0.003,"a":0.5,"b":0.25,"u":0.7,"m":0.08,"T":10,"p":0.15,"v":0.05,"g":0.98,"h":0,"d":0.03}

Historical alpha diagnostic: Small clinical effect and substantial substitution: Cost: $5.3M; New York City health QALYs: 0.03; all-population health QALYs: 0.03. Preserved20260914 health-only alpha; not current combined result. {"C":5267469,"N":2816,"f":0.5,"z":0.4,"delta":0.0005,"a":0.2,"b":0.1,"u":0.7,"m":0.08,"T":3,"p":0.05,"v":0.02,"g":0.98,"h":0,"d":0.03}

Historical alpha diagnostic: Stronger sustained clinical engagement: Cost: $5.3M; New York City health QALYs: 69.59; all-population health QALYs: 71.01. Preserved20260914 health-only alpha; not current combined result. {"C":5267469,"N":2816,"f":1,"z":0.8,"delta":0.01,"a":0.75,"b":0.5,"u":0.7,"m":0.08,"T":15,"p":0.3,"v":0.1,"g":0.98,"h":0,"d":0.03}

Historical alpha diagnostic: Complete funding substitution: Cost: $5.3M; New York City health QALYs: 0.00; all-population health QALYs: 0.00. Preserved20260914 health-only alpha; not current combined result. {"C":5267469,"N":2816,"f":0.8,"z":0.6,"delta":0.003,"a":0.5,"b":0,"u":0.7,"m":0.08,"T":10,"p":0.15,"v":0.05,"g":0.98,"h":0,"d":0.03}

Historical alpha diagnostic: No clinical benefit and one net QALY lost: Cost: $5.3M; New York City health QALYs: -0.98; all-population health QALYs: -1.00. Preserved20260914 health-only alpha; not current combined result. {"C":5267469,"N":2816,"f":0.8,"z":0.6,"delta":0,"a":0.5,"b":0.25,"u":0.7,"m":0.08,"T":10,"p":0,"v":0.05,"g":0.98,"h":1,"d":0.03}

Historical alpha diagnostic: Unrecognized resources increase cost 25%: Cost: $6.6M; New York City health QALYs: 3.91; all-population health QALYs: 3.99. Preserved20260914 health-only alpha; not current combined result. {"C":6584336.25,"N":2816,"f":0.8,"z":0.6,"delta":0.003,"a":0.5,"b":0.25,"u":0.7,"m":0.08,"T":10,"p":0.15,"v":0.05,"g":0.98,"h":0,"d":0.03}

Historical alpha diagnostic: Additional medication and referral resources: Cost: $5.8M; New York City health QALYs: 3.91; all-population health QALYs: 3.99. Preserved20260914 health-only alpha; not current combined result. {"C":5830669,"N":2816,"f":0.8,"z":0.6,"delta":0.003,"a":0.5,"b":0.25,"u":0.7,"m":0.08,"T":10,"p":0.15,"v":0.05,"g":0.98,"h":0,"d":0.03}

Counterfactual: Current grants, other hub/medical care, public naloxone, food/benefit routes and job support continue. b controls gift-induced engagement, a clinical equivalence only; economic incidence is separately net incremental, not multiplied by a again. Financial additionality is not applied twice.

Attribution: One unique overlapping cohort, no additive rescued lifetimes; only first-year high-risk mortality improvement. Morbidity/economic gains use baseline-alive cohort, no extra survival earnings. Buyer and unmet consumption strata disjoint; no public procurement/retail savings. Shared negative burden counted once, positive overlap reduces welfare rather than changing actual receipts.

Partial unweighted judgment scenarios, not a measured donor effect, confidence interval, source-vetted donor recommendation or complete EV. Current reach, generic utility, local hazard, gift capacity, funding replacement and net resource incidence unknown; observed inputs limited to filings and older page counts.

Sensitivity

  • Small clinical response, weak funding and net resource costs: no finite positive combined estimate; health=0.000023271542861183873; signed economic components independently inspectable.
  • Stronger additional engagement and useful household gains: $157K per DALY; health=0.061620520710886015; signed economic components independently inspectable.
  • No gift-induced expansion: no finite positive combined estimate; health=0; signed economic components independently inspectable.
  • No clinical change; extra burdens and no useful receipts: no finite positive combined estimate; health=-0.00516428620845315; signed economic components independently inspectable.
  • No mortality or morbidity benefit; signed resources remain: no finite positive combined estimate; health=-0.00010328572416906301; signed economic components independently inspectable.
  • Alternative care removes clinical advantage; engagement costs remain: no finite positive combined estimate; health=-0.00010328572416906301; signed economic components independently inspectable.
  • No useful food, consumption or workforce gain; costs remain: $2.3M per DALY; health=0.004611436122567768; signed economic components independently inspectable.
  • All positive economic welfare overlaps clinical wellbeing: $2.3M per DALY; health=0.004611436122567768; signed economic components independently inspectable.
  • All positive household welfare independent of health: $2.1M per DALY; health=0.004611436122567768; signed economic components independently inspectable.
  • Only 10% funded scale response: $5.6M per DALY; health=0.0018445744490271068; signed economic components independently inspectable.
  • 8% high-risk baseline hazard: $2.5M per DALY; health=0.0040701139168545135; signed economic components independently inspectable.
  • 2% high-risk baseline hazard: $2.1M per DALY; health=0.004936134791099415; signed economic components independently inspectable.
  • One-year engagement delay: $2.3M per DALY; health=0.004391952014453131; signed economic components independently inspectable.
  • Three-year survival valuation cap: $4.0M per DALY; health=0.0026641069584669693; signed economic components independently inspectable.
  • No donor-caused survival effect: $6.4M per DALY; health=0.001703476892861085; signed economic components independently inspectable.
  • No additional clinical utility change: $3.7M per DALY; health=0.002804673505537619; signed economic components independently inspectable.
  • Selected unrecognized medication/volunteer/public resources: $2.7M per DALY; health=0.004611436122567768; signed economic components independently inspectable.
  • 10K annual household consumption-resource reference: $2.3M per DALY; health=0.004611436122567768; signed economic components independently inspectable.
  • Net employment/disposable-pay effect negative: $2.3M per DALY; health=0.004611436122567768; signed economic components independently inspectable.

Unresolved inputs

  • Fresh annual unique clinical participant cohort, residence and repeated household mapping.
  • Dated uncovered operating package, staffing/clinical/workforce slots, public grant renewals, cash/receivable forecast and financial replacement response.
  • Observed local hazard, buprenorphine retention/discontinuation, additional naloxone response versus public alternatives and clinical utility/harm outcomes.
  • Actual food/hygiene purchase versus unmet-consumption incidence; net transport, medicine, benefits, lost pay and placement/disposable earnings.
  • External public-stock, medication/referral, volunteer/facility costs and displaced care; longer HIV/HCV, housing and other portfolio effects.

Health and income breakdown

For the modeled $10K: 0.00 health QALYs + 0.00 income-equivalent healthy years in New York City: $2.2M per DALY. Income equivalents are welfare comparisons, not observed QALYs or DALYs.

Method and caveats.

5. Funding and previous grants

The three original returns were freshly retrieved directly; the browser wrapper failed. Fiscal periods are July 2022–June 2023, July 2023–June 2024 and July 2024–June 2025. Full-recipient gross expense is $4,348,379/$5,106,419/$5,267,469, adding direct fundraising-event costs $73,846/$115,347/$95,881 to Part IX totals $4,274,533/$4,991,072/$5,171,588. The comparable annual mean is $4,907,422.33. The 2025 functional amounts $4,384,865 program, $602,749 management and $183,974 fundraising reconcile to Part IX, with direct events added once. 2023 original 2024 original 2025 original

Recognized noncash gifts $94,661/$95,182/$109,444 are not added again to reported expense merely because they are noncash. Latest [Schedule D](https://projects.propublica.org/nonprofits/full_text/202630649349300233/IRS990 ScheduleD) reconciles audit expense to Part IX without extra donated-service adjustment. Actual audit opinion/control findings were not newly reviewed; a Form 990 statement that an audit exists is not a fresh independent-audit acceptance. Latest government grants $4,469,690 dominate support; revenue $4,828,637 is net of event expense while the chosen gross cost denominator adds that expense back. The $342,951 deficit is unchanged when gross revenue/cost are treated consistently.

The 2025 balance sheet reports $291,414 cash, $1,940,700 pledges/grants receivable and $2,113,536 net assets without donor restrictions. Receivables, lease right-of-use assets/liabilities and equipment mean unrestricted net assets are not cash runway or proof of spare operating capacity. Grant timing, renewals, current restricted commitments, actual staffing/clinical slots and replacement funding are missing. A deficit suggests continuity questions, not a verified next-dollar treatment opportunity.

NYC's current provider route provides free naloxone and fentanyl strips to registered OOPPs. Its [May 2026 mail campaign](https://www.nyc.gov/site/doh/about/press/pr 2026/free-naloxone-by-mail-campaign.page) reports285,000 kits distributed citywide in 2025 and free mail/community routes. Supplies alone cannot identify SACHR's unique engagement or donor return. The workforce page names existing funders without grant amounts; no additional support package or available capacity is verified. No donation, contact, form submission or new restricted-gift arrangement was made.

Annual expenses

Organization-level spending, including programs, administration and fundraising. The research list averages three comparable, consecutive full fiscal years when available.

  • FY 2023: $4.3M; St. Ann's Corner of Harm Reduction Inc., EIN 13-3724008, 12-month period, Accrual Form 990 gross expense plus separately netted event cost; no additional Schedule D donated-service adjustment.. Source
  • FY 2024: $5.1M; St. Ann's Corner of Harm Reduction Inc., EIN 13-3724008, 12-month period, Accrual Form 990 gross expense plus separately netted event cost; no additional Schedule D donated-service adjustment.. Source
  • FY 2025: $5.3M; St. Ann's Corner of Harm Reduction Inc., EIN 13-3724008, 12-month period, Accrual Form 990 gross expense plus separately netted event cost; no additional Schedule D donated-service adjustment.. Source

6. Sources

  1. FY2023 original IRS990. St. Ann's Corner / IRS. Published: not stated; retrieved: 2026-10-04.
  2. FY2023 original IRS990ScheduleD. St. Ann's Corner / IRS. Published: not stated; retrieved: 2026-09-14.
  3. FY2024 original IRS990. St. Ann's Corner / IRS. Published: not stated; retrieved: 2026-10-04.
  4. FY2024 original IRS990ScheduleD. St. Ann's Corner / IRS. Published: not stated; retrieved: 2026-09-14.
  5. FY2025 original IRS990. St. Ann's Corner / IRS. Published: not stated; retrieved: 2026-10-04.
  6. FY2025 original IRS990ScheduleD. St. Ann's Corner / IRS. Published: not stated; retrieved: 2026-10-04.
  7. Current health-hub programs. St. Ann's Corner. Published: not stated; retrieved: 2026-10-04.
  8. Annual participant scale, linked to 2023 report. St. Ann's Corner. Published: not stated; retrieved: 2026-10-04.
  9. 2023 annual report; image-only original visually inspected. St. Ann's Corner. Published: not stated; retrieved: 2026-09-14.
  10. Mortality during and after opioid substitution treatment. Sordo et al. / BMJ. Published: 2017-04-26; retrieved: 2026-09-14.
  11. Community overdose-prevention implementation randomized trial. HEALing Communities investigators / NEJM. Published: 2024-06-16; retrieved: 2026-09-14.
  12. Ordinary donation route. St. Ann's Corner. Published: not stated; retrieved: 2026-10-04.
  13. Public naloxone and program supply routes. NYC Health. Published: not stated; retrieved: 2026-10-04.
  14. May 2026 free naloxone mail campaign. NYC Health. Published: not stated; retrieved: 2026-10-04.
  15. Current South Bronx outreach scope. SACHR. Published: not stated; retrieved: 2026-09-14.
  16. Current LUCHA workforce initiative and enrollment. SACHR. Published: not stated; retrieved: 2026-10-04.
  17. Current drop-in, meal and hygiene services. SACHR. Published: not stated; retrieved: 2026-10-04.
  18. Original Sordo mortality synthesis: abstract and methods XML. Sordo et al. / BMJ via EuropePMC. Published: 2017-04-26; retrieved: 2026-10-04.
  19. Original British Columbia OAT/fentanyl mortality cohort XML. Pearce et al. / BMJ via EuropePMC. Published: 2020-03-31; retrieved: 2026-10-04.
  20. Randomized Communities That HEAL secondary MOUD outcomes. Brown et al. / Drug and Alcohol Dependence. Published: 2025-07-09; retrieved: 2026-10-04.
  21. Published health/log-income welfare comparison. Coefficient Giving. Published: not stated; retrieved: 2026-10-04.